STOCK TITAN

Atea Pharmaceuticals, Inc. - $AVIR STOCK NEWS

Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: $AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to discovering, developing, and commercializing oral antiviral therapies aimed at treating severe viral diseases. Founded in 2012, Atea focuses on addressing unmet medical needs, particularly in serious viral infections caused by single-stranded RNA viruses.

The company's leading product candidate is AT-527 (bemnifosbuvir), an antiviral agent developed for treating COVID-19, caused by the SARS-CoV-2 virus. Currently, AT-527 is undergoing Phase 3 clinical trials. Additionally, the combination of bemnifosbuvir and ruzasvir, an oral NS5A inhibitor, is being developed for treating Hepatitis C Virus (HCV) and has shown promising results in Phase 2 trials. This combination therapy aims to provide a highly potent pan-genotypic antiviral treatment with a short treatment duration and fewer contraindications, particularly beneficial for HCV patients.

Beyond COVID-19 and HCV, Atea is also advancing other antiviral therapies in its pipeline, including AT-787 for Hepatitis C (under Phase 2 clinical trial), AT-752 for Dengue (under Phase 2 trial), and other candidates like AT-889 and AT-934 for Respiratory Syncytial Virus (currently under clinical trials).

Recent achievements include positive initial data from a Phase 2 study of bemnifosbuvir and ruzasvir for HCV, showing a 97% sustained virologic response rate at 12 weeks post-treatment. Furthermore, Atea has completed enrollment for the Phase 3 SUNRISE-3 trial for treating high-risk COVID-19 patients, with results expected in the second half of 2024.

Financially, Atea reported a solid cash position of $578.1 million as of December 31, 2023, enabling them to continue advancing their clinical programs. Collaborations and strategic partnerships play a crucial role in Atea’s progress, helping to broaden its scope and enhance its therapeutic offerings.

Investors and stakeholders can stay informed about Atea’s developments through their regular updates, financial reports, and participation in industry conferences. For more information, visit their official website at www.ateapharma.com.

Rhea-AI Summary

Atea Pharmaceuticals announced positive initial results from their Phase 2 study combining bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). The lead-in cohort of 60 patients showed a 97% sustained virologic response rate at 12 weeks post-treatment (SVR12) following an 8-week regimen. This combination therapy displayed high antiviral potency, short treatment duration, low risk of drug interaction, and a high barrier to resistance.

Additionally, a 100% SVR12 rate was observed in patients with the difficult-to-treat genotype 3. The study reported no severe drug-related adverse events or treatment discontinuations. Atea aims to enroll up to 220 more subjects, including those with compensated cirrhosis. These promising results were shared at the EASL Congress in Milan, Italy, from June 5-8, 2024, highlighting the potential best-in-class profile of the drug combination.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.04%
Tags
-
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical firm focused on developing oral antiviral treatments for severe viral diseases, announced that CEO and Founder Jean-Pierre Sommadossi, PhD, will present a business update at the Jefferies Healthcare Conference. The presentation is scheduled for June 5, 2024, at 10:30 a.m. ET in New York. Both a live and archived webcast of the presentation will be accessible on Atea's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
conferences
-
Rhea-AI Summary

Atea Pharmaceuticals will present new data on the combination of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV) at the EASL Congress 2024. The presentations will showcase antiviral efficacy, including SVR12 data from the ongoing Phase 2 HCV trial's lead-in cohort. Preclinical data highlight bemnifosbuvir's high resistance barrier and pharmacokinetics, and ruzasvir's low risk of drug-drug interactions. The full dataset will be available on the EASL Congress website on June 5, 2024. HCV remains a significant health issue in the U.S., with over 2 million chronic cases and annual diagnoses outpacing cure rates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
none
Rhea-AI Summary

Atea Pharmaceuticals reported Q1 2024 financial results, highlighting key developments in their COVID-19 and HCV treatment trials. The company completed enrollment in the global Phase 3 SUNRISE-3 trial for bemnifosbuvir in high-risk COVID-19 patients, with results expected in H2 2024. Additionally, they are progressing in their Phase 2 trial for HCV treatment with bemnifosbuvir and ruzasvir, also expecting results in H2 2024. Financially, Atea reported a net loss of $63.2 million, up from $35.5 million YoY, primarily due to increased R&D expenses. Cash and equivalents stood at $541.5 million, down from $578.1 million at the end of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
-
Rhea-AI Summary

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) will host a conference call on May 14, 2024, to report financial results for the first quarter ended March 31, 2024, and provide a business update. Participants can access the live webcast on the company's Investor Relations website. Telephone registration is required for participation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
conferences earnings
-
Rhea-AI Summary

Atea Pharmaceuticals, Inc. announced the Phase 1 data presentation at ESCMID Global 2024, highlighting the favorable safety profile of bemnifosbuvir, an oral nucleotide polymerase inhibitor. The results show no cardiotoxicity in healthy participants, supporting the drug's safety profile. Atea aims to address the unmet need for COVID-19 and HCV treatments. Phase 3 SUNRISE-3 trial for COVID-19 and Phase 2 trial for HCV are upcoming in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Atea Pharmaceuticals completes enrollment of over 2,200 high-risk patients in SUNRISE-3 trial for bemnifosbuvir monotherapy cohort. Results expected in 2H’24. Fast Track designation by FDA for COVID-19 treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.1%
Tags
clinical trial covid-19
-
Rhea-AI Summary
Atea Pharmaceuticals, Inc. (AVIR) reports a 98% SVR4 rate in Phase 2 HCV study, surpassing 1,400 COVID-19 patient enrollment in Phase 3 SUNRISE-3 study. Financial results for Q4 and full year 2023 show strong operational execution and progress in clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
-
Rhea-AI Summary
Atea Pharmaceuticals, Inc. (AVIR) will host a live conference call to report financial results for Q4 and full year 2023, along with a business update on February 28, 2024, at 4:30 p.m. ET. Participants can access the call via webcast or telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.77%
Tags
conferences earnings
Rhea-AI Summary
Atea Pharmaceuticals, Inc. (AVIR) Achieves 98% Sustained Virologic Response in Phase 2 HCV Study and Surpasses 650 Patients Enrollment in Phase 3 COVID-19 Trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.29%
Tags
clinical trial covid-19

FAQ

What is Atea Pharmaceuticals, Inc.?

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing oral antiviral therapies for severe viral diseases.

What are the main products developed by Atea Pharmaceuticals?

Atea's lead product candidate is AT-527 (bemnifosbuvir) for COVID-19, and they are also developing a combination of bemnifosbuvir and ruzasvir for Hepatitis C Virus (HCV).

What is the status of the AT-527 (bemnifosbuvir) clinical trials?

AT-527 is currently in Phase 3 clinical trials for treating COVID-19, with significant progress reported in patient enrollment and trial milestones.

What recent achievements has Atea Pharmaceuticals made?

Recent achievements include the completion of Phase 3 SUNRISE-3 trial enrollment for COVID-19 and positive initial data from a Phase 2 study of bemnifosbuvir and ruzasvir for HCV.

Where is Atea Pharmaceuticals headquartered?

Atea Pharmaceuticals is headquartered in Boston, Massachusetts.

How does Atea Pharmaceuticals plan to address unmet medical needs?

Atea aims to address unmet medical needs by developing potent, short-duration antiviral therapies with fewer contraindications, particularly for serious viral infections like HCV and COVID-19.

What is the financial condition of Atea Pharmaceuticals?

As of December 31, 2023, Atea reported a strong cash position of $578.1 million, supporting the advancement of their clinical programs and operations.

How can I get more information about Atea Pharmaceuticals?

For more information, visit Atea Pharmaceuticals' official website at www.ateapharma.com.

What are the expected upcoming events for Atea Pharmaceuticals?

Upcoming events include the anticipated release of full results from the ongoing Phase 2 HCV study and the Phase 3 SUNRISE-3 COVID-19 trial in the second half of 2024.

Who should be interested in Atea Pharmaceuticals’ updates?

Investors, stakeholders, healthcare professionals, and patients interested in advancements in antiviral therapies for serious viral infections should follow Atea Pharmaceuticals’ updates.

Atea Pharmaceuticals, Inc.

Nasdaq:AVIR

AVIR Rankings

AVIR Stock Data

330.15M
63.74M
9.46%
67.46%
1.98%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOSTON

About AVIR

atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.